Revision 3

#94032Store at -20C

Cell Signaling Technology

Orders: 877-616-CELL (2355) [email protected]

Support: 877-678-TECH (8324)

Web: [email protected] cellsignal.com

3 Trask LaneDanversMassachusetts01923USA
For Research Use Only. Not for Use in Diagnostic Procedures.
Applications:

WB, IP, ChIP, ChIP-seq

REACTIVITY:

H Mk

SENSITIVITY:

Endogenous

MW (kDa):

100

Source/Isotype:

Rabbit IgG

UniProt ID:

#Q15059

Entrez-Gene Id:

8019

Product Information

Product Usage Information

For optimal ChIP and ChIP-seq results, use 10 μL of antibody and 10 μg of chromatin (approximately 4 × 106 cells) per IP. This antibody has been validated using SimpleChIP® Enzymatic Chromatin IP Kits.
Application Dilution
Western Blotting 1:1000
Immunoprecipitation 1:200
Chromatin IP 1:50
Chromatin IP-seq 1:50

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

BRD3 (E3D5N) Rabbit mAb recognizes endogenous levels of total BRD3 protein.

Species Reactivity:

Human, Monkey

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala10 of human BRD3 protein.

Background

Bromodomain-containing protein 3 (BRD3), also known as ORFX, is a member of the bromodomains and extra terminal (BET) family of proteins, which also includes BRD2, BRD4, and BRDT (1-3). BET family proteins contain two tandem bromodomains and an extra terminal (ET) domain, and bind acetyl lysine residues (3). BRD3 is capable of binding acetylated histone H3 Lys14 as well as acetylated histone H4 Lys5 and Lys12 to promote transcription (4). BRD3 plays a role in erythroid development by binding to GATA1 to facilitate its binding to target genes (5). Similar to BRD4, the BRD3 gene can be fused to NUT in NUT midline carcinomas (6). Investigators have found molecular inhibition of BET proteins to be effective in inducing apoptosis in various MLL-fusion driven leukemic cell lines by competing BRD3 and BRD4 from chromatin, leading to reduced expression of BCL2, Myc, and CDK6 (7).

  1. Belkina, A.C. and Denis, G.V. (2012) Nat Rev Cancer 12, 465-77.
  2. Voigt, P. and Reinberg, D. (2011) Genome Biol 12, 133.
  3. Wu, S.Y. and Chiang, C.M. (2007) J Biol Chem 282, 13141-5.
  4. LeRoy, G. et al. (2008) Mol Cell 30, 51-60.
  5. Lamonica, J.M. et al. (2011) Proc Natl Acad Sci USA 108, E159-68.
  6. French, C.A. et al. (2008) Oncogene 27, 2237-42.
  7. Dawson, M.A. et al. (2011) Nature 478, 529-33.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Applications Key

WB: Western Blotting IP: Immunoprecipitation ChIP: Chromatin IP ChIP-seq: Chromatin IP-seq

Cross-Reactivity Key

H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

Revision 3
#94032

BRD3 (E3D5N) Rabbit mAb

Western Blotting Image 1: BRD3 (E3D5N) Rabbit mAb Expand Image
Western blot analysis of extracts from various cell lines using BRD3 (E3D5N) Rabbit mAb (upper) or β-Actin (D6A8) Rabbit mAb #8457 (lower). Low expression of BRD3 protein in NCI-H929 cells is consistent with the predicted expression pattern.
Western Blotting Image 2: BRD3 (E3D5N) Rabbit mAb Expand Image
Western blot analysis of extracts from 293T cells, transfected with control siRNA (-) or human BRD3 siRNA (hBRD3 siRNA; +), using BRD3 (E3D5N) Rabbit mAb (upper) or β-Actin (D6A8) Rabbit mAb #8457 (lower).
Immunoprecipitation Image 1: BRD3 (E3D5N) Rabbit mAb Expand Image
Immunoprecipitation of BRD3 protein from HeLa cell extracts. Lane 1 is 10% input, lane 2 is Rabbit (DA1E) mAb IgG XP® Isotype Control #3900, and lane 3 is BRD3 (E3D5N) Rabbit mAb. Western blot analysis was performed using BRD3 (E3D5N) Rabbit mAb. Anti-rabbit IgG, HRP-linked Antibody #7074 was used as a secondary antibody.
Chromatin Immunoprecipitation Image 1: BRD3 (E3D5N) Rabbit mAb Expand Image

Chromatin immunoprecipitations were performed with cross-linked chromatin from MV-4-11 cells and BRD3 (E3D5N) Rabbit mAb, using SimpleChIP® Plus Enzymatic Chromatin IP Kit (Magnetic Beads) #9005. DNA Libraries were prepared using DNA Library Prep Kit for Illumina Systems (ChIP-seq, CUT&RUN) #56795. The figure shows binding across Myc, a known target gene of BRD3 (see additional figure containing ChIP-qPCR data).

Chromatin Immunoprecipitation Image 2: BRD3 (E3D5N) Rabbit mAb Expand Image
Chromatin immunoprecipitations were performed with cross-linked chromatin from MV-4-11 cells and BRD3 (E3D5N) Rabbit mAb, using SimpleChIP® Plus Enzymatic Chromatin IP Kit (Magnetic Beads) #9005. DNA Libraries were prepared using DNA Library Prep Kit for Illumina Systems (ChIP-seq, CUT&RUN) #56795. The figures show binding across MYC (upper) and BCL2 (lower), known target genes of BRD3 (see additional figure containing ChIP-qPCR data).
Chromatin Immunoprecipitation Image 3: BRD3 (E3D5N) Rabbit mAb Expand Image

Chromatin immunoprecipitations were performed with cross-linked chromatin from MV-4-11 cells and either BRD3 (E3D5N) Rabbit mAb or Normal Rabbit IgG #2729, using SimpleChIP® Plus Enzymatic Chromatin IP Kit (Magnetic Beads) #9005. The enriched DNA was quantified by real-time PCR, using human c-Myc promoter primers, human BCL2 promoter primers, and SimpleChIP® Human α Satellite Repeat Primers #4486. The amount of immunoprecipitated DNA in each sample is represented as signal relative to the total amount of input chromatin, which is equivalent to one.